Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Referanser til kreft i spiserør

  1. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med spiserørskreft.  [Online] September 2008 [hentet 27.oktober2008]; tilgjengelig fra: URL: http://www.shdir.no/vp/multimedia/archive/00021/Nasjonalt_handlingsp_21459a.pdf
  2. Lin CC, Papadopoulos KP. Novel targeted therapies for advanced esophageal cancer. Dis Esophagus 2007; 20(5):365-71.
  3. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345(10):725-30.
  4. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007; 8(6):545-53.
  5. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg 1990; 77(8):845-57.
  6. Pech O, May A, Rabenstein T, Ell C. Endoscopic resection of early oesophageal cancer. Gut 2007; 56(11):1625-34.
  7. Raja SG, Salhiyyah K, Nagarajan K. Does neoadjuvant chemotherapy improve survival in patients with resectable thoracic oesophageal cancer? Interact Cardiovasc Thorac Surg 2007; 6(5):661-4.
  8. Rankin SC. Oesophageal cancer: assessment of response and follow up. Cancer Imaging 2007; 7 Spec No A:S67-9.:S67-S69.
  9. Pennathur A, Luketich JD. Resection for esophageal cancer: strategies for optimal management. Ann Thorac Surg 2008; 85(2):S751-S756.
  10. DeMeester SR. New options for the therapy of Barrett's high-grade dysplasia and intramucosal adenocarcinoma: endoscopic mucosal resection and ablation versus vagal-sparing esophagectomy. Ann Thorac Surg 2008; 85(2):S747-S750.
  11. Schuchert MJ, Luketich JD. Management of Barrett's esophagus. Oncology (Williston Park) 2007; 21(11):1382-9, 1392.
  12. Law S, Wong J. The current management of esophageal cancer. Adv Surg 2007; 41:93-119.:93-119.
  13. Rankin SC. Oesophageal cancer: assessment of response and follow up. Cancer Imaging 2007; 7 Spec No A:S67-9.:S67-S69.
  14. Nathwani RA, Kowalski T. Endoscopic stenting of esophageal cancer: the clinical impact. Curr Opin Gastroenterol 2007; 23(5):535-8.
  15. Lin CC, Papadopoulos KP. Novel targeted therapies for advanced esophageal cancer. Dis Esophagus 2007; 20(5):365-71.
  16. Raja SG, Salhiyyah K, Nagarajan K. Does neoadjuvant chemotherapy improve survival in patients with resectable thoracic oesophageal cancer? Interact Cardiovasc Thorac Surg 2007; 6(5):661-4.
  17. Gardner-Thorpe J, Hardwick RH, Dwerryhouse SJ. Salvage oesophagectomy after local failure of definitive chemoradiotherapy. Br J Surg 2007; 94(9):1059-66.
  18. Upponi S, Ganeshan A, Slater A et al. Imaging following surgery for oesophageal cancer. Clin Radiol 2007; 62(8):724-31.
  19. Liao Z, Cox JD, Komaki R. Radiochemotherapy of esophageal cancer. J Thorac Oncol 2007; 2(6):553-68.
  20. Siersema PD. Pathogenesis, diagnosis and therapeutic possibilities of esophageal cancer. Curr Opin Gastroenterol 2007; 23(4):456-61.
  21. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007; 8(6):545-53.
  22. Kato H, Fukuchi M, Miyazaki T et al. Surgical treatment for esophageal cancer. Current issues. Dig Surg 2007; 24(2):88-95.
  23. Cancer in Norway 2015, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway

 

Prosedyrer i Oncolex kan ikke erstatte faglig veiledning fra kvalifisert veileder. Den som følger prosedyrene har et selvstendig ansvar for at det foreligger nødvendig godkjenning, lisens eller autorisasjon.
Oslo universitetssykehus HF © 2016